Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena

    ... months (range 6-46 months). Parameters of hemolysis , transfusion requirements, and serum iron parameters were analyzed. Lactate ... low reticulocyte production index and/or requiring blood transfusions. Monospecific direct Coombs test was positive in most PNH ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

    ... Journal Title:  J Blood Med Primary Author:  ... del(5q) MDS, including reduction in red blood cell transfusion requirements and improvements in quality of life. Lenalidomide has ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Iron overload in myelodysplastic syndromes: diagnosis and management.

    ... stem cell malignancies characterized by ineffective blood cell production. Many MDS patients are dependent on red blood cell ... MDS whose expected survival is measured in years. Transfusion dependence is associated with shorter survival and an increased ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Costs and quality of life in patients with myelodysplastic syndromes.

    ... Journal Title:  Am J Blood Res Primary Author:  ... and the impact on quality of life (QOL) of MDS-separately in transfusion-independent (TI) and -dependent (TD) patients-a literature search ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

    ... is approved for the treatment of patients who have transfusion-dependent anemia due to lower-risk MDS with chromosome 5q ... that lenalidomide is effective not only in reducing red blood cell (RBC) transfusion burden, but also in modifying the disease ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?

    ... Erythropoiesis-stimulating agents (ESA) may reduce red blood cell transfusion requirements. MDS patients receiving ESA were reviewed for ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Iron chelation therapy in myelodysplastic syndromes.

    ... including efficacy, safety, and economic considerations for transfusion-dependent patients with MDS, is provided. SUMMARY: ... treatment. Supportive care measures such as red blood cell transfusions and erythroid colony stimulating factors are ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study

    ... with reduced overall survival were increasing age, transfusion dependency (defined as having received at least one red blood cell transfusion every 8 weeks over a period of 4 months), Eastern ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

    ... leukaemia (AML). Most MDS patients eventually require transfusion of red blood cells for anaemia, placing them at risk of transfusional iron ... patients may have improvement in cell counts and decreased transfusion requirements. While guidelines for MDS generally recommend ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous ... Risk-adapted therapy: Therapy is selected based on risk, transfusion needs, percent of bone marrow blasts and more recently cytogenetic ...

    Research Article last updated 07/20/2018 - 5:15pm.